Key facts
- OVO Biomanufacturing’s last known valuation is $3.6M (Apr 2025).
- It has raised $1.2M; the latest was Seed Round ($900K) in Apr 2025.
- Notable investors include Innovate UK, University of Warwick Foundation, Catapult Ventures, Coventry University, Oxford Technology Management — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for OVO Biomanufacturing
- ·The full record, as it builds
Funding rounds
No funding rounds for OVO Biomanufacturing are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About OVO Biomanufacturing
Developer of a software-based biotechnology platform designed to manage defective interfering particles during viral vaccine manufacturing. The company uses next-generation sequencing data to analyse defective interfering particle populations and provide recommendations on growth conditions to optimise working seed stocks, enabling viral vaccine manufacturers to reduce the impact of defective interfering particles and maximise viral yield during vaccine production.
- Sector
- Healthcare
- HQ
- Coventry, United Kingdom
- Founded
- 2019
- Employees
- 6
- Website
- ovobiomanufacturing.com/
- Ownership
- Privately Held (backing)
OVO Biomanufacturing doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in OVO Biomanufacturing shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on OVO Biomanufacturing in its N-PORT filings yet. We sweep new filings monthly.